Rep. Mike Gallagher (R-WI), the lead sponsor of a closely watched bill that would prevent many US biopharma companies from doing business with WuXi and potentially other Chinese biopharma companies, is leaving his post next month, the congressman announced Friday.
Gallagher, who chairs the House Select Committee on the Chinese Communist Party, had previously announced his plans to not run for re-election next November, but he will now leave office April 19. It’s unclear if his departure will hurt the chances of passing the bill, known as the BIOSECURE Act, as it gained traction among other lawmakers across both chambers of Congress and on both sides of the aisle.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.